[{"address1": "9119 Gaither Road", "city": "Gaithersburg", "state": "MD", "zip": "20877", "country": "United States", "phone": "301 825 9810", "website": "https://www.neximmune.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.", "fullTimeEmployees": 6, "companyOfficers": [{"maxAge": 1, "name": "Ms. Kristi  Jones R.Ph.", "age": 60, "title": "CEO, President & Director", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 989279, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mathias  Oelke Ph.D.", "age": 55, "title": "Chief Scientific Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 605776, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Trainer M.B.A.", "age": 49, "title": "Consultant", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 1326152, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Albert Nicholas Marchio II", "age": 71, "title": "Interim CFO & Principal Accounting Officer", "yearBorn": 1952, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen  Haslbeck", "title": "Head of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Daniel P. Bednarik", "title": "Senior Vice President of Molecular Engineering & Protein Design", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert Douglas Knight M.D.", "age": 72, "title": "Chief Medical Officer", "yearBorn": 1951, "fiscalYear": 2023, "totalPay": 454771, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Chad  Rubin", "title": "Senior Vice President of Corporate Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jack A. Ragheb M.D., Ph.D.", "title": "Senior Vice President of Translational Science", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Schiller", "title": "Head of Business Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 8, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1722470400, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "open": 0.83, "dayLow": 0.83, "dayHigh": 0.83, "regularMarketOpen": 0.83, "regularMarketDayLow": 0.83, "regularMarketDayHigh": 0.83, "beta": 1.93, "forwardPE": -0.21893333, "volume": 5, "regularMarketVolume": 5, "averageVolume": 621775, "averageVolume10days": 3290, "averageDailyVolume10Day": 3290, "bid": 0.82, "ask": 1.01, "bidSize": 40000, "askSize": 40000, "marketCap": 1145024, "fiftyTwoWeekLow": 0.82, "fiftyTwoWeekHigh": 28.695, "fiftyDayAverage": 2.23582, "twoHundredDayAverage": 4.34531, "trailingAnnualDividendYield": "NaN", "currency": "USD", "enterpriseValue": -1279087, "floatShares": 1178371, "sharesOutstanding": 1394670, "sharesShort": 15988, "sharesShortPriorMonth": 12317, "sharesShortPreviousMonthDate": 1717113600, "dateShortInterest": 1719532800, "sharesPercentSharesOut": 0.0117, "heldPercentInsiders": 0.16722, "heldPercentInstitutions": 0.10719, "shortRatio": 2.26, "shortPercentOfFloat": 0.012999999, "bookValue": 0.499, "priceToBook": 1.6452905, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -20616850, "trailingEps": -18.51, "forwardEps": -3.75, "enterpriseToEbitda": 0.078, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "NEXI", "underlyingSymbol": "NEXI", "shortName": "NexImmune, Inc.", "longName": "NexImmune, Inc.", "firstTradeDateEpochUtc": 1613140200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "eee25fcf-0d1b-3bd4-bd23-9a9f57c2d9b7", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.821, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 2424112, "totalCashPerShare": 1.738, "ebitda": -16375748, "quickRatio": 0.512, "currentRatio": 0.66, "returnOnAssets": -0.72695, "returnOnEquity": -2.32974, "freeCashflow": -7099758, "operatingCashflow": -17605236, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-19"}]